- Starpharma (SPL) has signed an ongoing distribution arrangement to launch its VIRALEZE antiviral nasal spray in Vietnam
- The deal involves a minimum commitment of at least one million units of VIRALEZE in the first year, and will see the spray available in Vietnam to consumers through clinics, hospitals, and pharmacies
- The ongoing agreement is exclusive for Vietnam and follows an initial supply contract for VIRALEZE signed in October
- The new deal has an initial five-year term with the option for annual extensions
- Starpharma shares were up 1.71 per cent to trade at $1.19
Starpharma (SPL) has signed an ongoing distribution arrangement to launch VIRALEZE in Vietnam.
VIRALEZE is an antiviral nasal spray which provides a physical barrier to trap and inactivate viruses, including SARS-CoV-2.
The deal was penned with Healthco Australia (HealthCo) and Vietnam-based Truong Bao Land (TBL), Nam Thanh Trade (NTT) and Medical Services Company, and involves a minimum commitment of at least one million units of VIRALEZE in the first year.
This ongoing agreement with HealthCo is exclusive for Vietnam and follows an initial supply contract for VIRALEZE signed in October.
The agreement has an initial five-year term with the option for annual extensions.
Starpharma will supply the product, while TBL and NTT will be responsible for sales, distribution, and marketing of the product locally in Vietnam. The nasal spray will be available in Vietnam to retail consumers, clinics, hospitals, and pharmacies through the local medical distribution networks in Vietnam
“We are delighted to see our partners launch VIRALEZE in Vietnam so rapidly, particularly given the current Delta outbreak across the country,” Starpharma CEO Dr Jackie Fairley commented.
“Starpharma continues to advance its discussions with potential commercial partners elsewhere in multiple countries in Europe, Asia, the Middle East, and India.”
Starpharma shares were up 1.71 per cent to trade at $1.19 at 10:44 am AEDT.